Spiolto Respimat

Spiolto Respimat is a fixed-dose combination inhaler containing tiotropium (2.5 mcg) and olodaterol (2.5 mcg) per actuation, delivered via the Respimat Soft Mist inhaler device. It combines a long-acting muscarinic antagonist (LAMA) with a long-acting beta-2 agonist (LABA) in a single inhaler, providing dual bronchodilation for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults. The standard dose is two actuations once daily, delivering 5 mcg tiotropium and 5 mcg olodaterol.

Dual Bronchodilation in COPD

COPD is characterised by fixed or partially reversible airflow limitation resulting from a combination of small airways disease and emphysema. Bronchodilators are central to COPD management, reducing airway smooth muscle tone, dynamic hyperinflation, and the work of breathing. LAMA/LABA combinations are recommended in international guidelines (including GOLD) for patients with COPD whose symptoms are insufficiently controlled by monotherapy.

Tiotropium, the LAMA component, blocks M1, M2, and M3 muscarinic receptors in airway smooth muscle, reducing acetylcholine-driven bronchoconstriction and glandular secretion. Olodaterol, the LABA component, stimulates beta-2 adrenoceptors to produce sustained smooth muscle relaxation. The two mechanisms are complementary and clinically synergistic, providing greater FEV1 improvements and symptom relief than either component alone.

The Respimat Soft Mist Inhaler

The Respimat device delivers a slow-moving, fine aqueous aerosol rather than the rapid propellant-driven burst of a pressurised metered-dose inhaler. This lower velocity and longer spray duration improve lung deposition and reduce oropharyngeal impaction, potentially improving efficacy in patients with suboptimal inhalation technique. The device is breath-actuated and does not require inspiratory effort to be coordinated with canister pressing, making it more accessible to elderly patients or those with impaired coordination.

Indication: COPD Only

Spiolto Respimat is indicated exclusively for COPD and is not licensed or appropriate for the treatment of asthma. LABA monotherapy (without ICS) in asthma carries significant safety risks, and the absence of an ICS in Spiolto makes it wholly unsuitable for asthmatic patients. Patients with confirmed asthma-COPD overlap syndrome require specialist guidance on appropriate combination therapy.

Spiolto Respimat is inhaled once daily, every day at the same time. Two actuations are required to deliver the full therapeutic dose; these should be taken consecutively. The inhaler should be kept upright with the cap closed between uses.

Preparing and Using the Respimat Inhaler

Before first use, the inhaler must be prepared: hold it upright, turn the clear base in the direction of the arrows until it clicks, then open the cap fully and breathe out slowly away from the mouthpiece. Place the mouthpiece between the lips without covering the air vents on the sides, tilt the head back slightly, and press the dose release button while inhaling slowly and deeply through the mouth. Hold the breath for 10 seconds, then repeat immediately for the second actuation. The cap should be closed after use.

Patients should not inhale through the nose during use, and should avoid breathing out into the mouthpiece. The mouthpiece should be cleaned regularly with a damp cloth to prevent blockage. A dose counter on the inhaler indicates the remaining doses, allowing timely ordering of a replacement.

Maintenance Use Only

Spiolto Respimat is a maintenance inhaler and should not be used for relief of acute breathlessness or COPD exacerbations. Patients must have a short-acting bronchodilator such as salbutamol or ipratropium available for immediate symptom relief. If breathlessness suddenly worsens or reliever use increases significantly, urgent medical assessment is required.

The standard dose of Spiolto Respimat is two actuations (2.5 mcg tiotropium + 2.5 mcg olodaterol per actuation) once daily, delivering a total daily dose of 5 mcg tiotropium and 5 mcg olodaterol. The two actuations should be taken consecutively once per day.

No dose adjustment is required in elderly patients. In patients with mild-to-moderate renal impairment, the standard dose can be used, but clinical monitoring is recommended as tiotropium is primarily renally excreted. In severe renal impairment (creatinine clearance below 30 ml/min), the benefits should be carefully weighed against risks, as plasma tiotropium levels may increase substantially. Spiolto Respimat is not recommended in patients with severe renal impairment unless benefits clearly outweigh risks. Hepatic impairment does not significantly affect tiotropium pharmacokinetics, as it undergoes minimal hepatic metabolism.

Common Side Effects

• Dry mouth, related to the anticholinergic effect of tiotropium
• Nasopharyngitis (runny or blocked nose, sore throat)
• Upper respiratory tract infections
• Urinary tract infection
• Headache
• Tremor or palpitations related to olodaterol's beta-2 stimulation
• Constipation (anticholinergic effect)

Serious Side Effects

• Urinary retention, men with benign prostatic hyperplasia are at particular risk; seek medical attention if unable to pass urine
• Acute angle-closure glaucoma, if the aerosol contacts the eye; presents as sudden severe eye pain, halos around lights, and blurred vision; requires immediate ophthalmological care
• Paradoxical bronchospasm, sudden worsening of breathing after inhalation; discontinue immediately and use a short-acting reliever
• Atrial fibrillation and other cardiac arrhythmias, particularly in patients with pre-existing cardiac disease
• Hypokalaemia, particularly when combined with corticosteroids or diuretics

Spiolto Respimat must not be used in asthma. It contains no inhaled corticosteroid, and the LABA component (olodaterol) used without ICS in asthma significantly increases the risk of severe or fatal asthma attacks. Patients with any degree of asthma should not be prescribed this medicine.

Anticholinergic Precautions

The tiotropium component of Spiolto carries the anticholinergic side effects common to LAMA agents. Patients with urinary retention, symptomatic benign prostatic hyperplasia, or bladder outflow obstruction are at risk of acute urinary retention and should be monitored carefully. The medicine should be used with extreme caution in patients with narrow-angle glaucoma. Care must be taken to avoid accidental contact of the aerosol spray with the eyes, as this can precipitate acute angle-closure glaucoma.

Concurrent use of other anticholinergic agents is not recommended, as additive antimuscarinic effects may occur. This includes medicines such as ipratropium, aclidinium, and glycopyrronium, as well as systemic anticholinergics.

Cardiovascular Considerations

Both components of Spiolto can affect the cardiovascular system. Olodaterol, as a beta-2 agonist, may cause tachycardia, palpitations, and hypokalaemia, particularly at initiation. Tiotropium has been associated with cardiovascular events including atrial fibrillation in some studies. Spiolto should be used with caution in patients with known ischaemic heart disease, arrhythmia, or heart failure. Any new or worsening cardiac symptoms should prompt medical review.

• Hypersensitivity to tiotropium bromide, olodaterol, or any excipient including benzalkonium chloride
• Use in asthma (licensed for COPD only)
• Use as a reliever for acute bronchospasm or COPD exacerbation
• Concurrent use with other long-acting muscarinic antagonists or long-acting beta-2 agonists (duplication of class)
• Uncontrolled narrow-angle glaucoma without ophthalmological supervision
• Urinary retention (relative contraindication; use with extreme caution)
• Symptomatic bradyarrhythmias where beta-2 stimulation is hazardous
• Children and adolescents under 18 years